4-methyl-7-methylamino-2-(azepan-1-yl)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 4-methyl-7-methylamino-2-(azepan-1-yl)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
• 英文别名: 2-(hexahydro-1H-azepin-1-yl)-N,8-dimethyl-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridin-5-amine；4-(azepan-1-yl)-N,12-dimethyl-5-thia-3,7,10,12-tetraazatricyclo[7.3.0.0^{2,6}]dodeca-1(9),2(6),3,7,10-pentaen-8-amine；4-(azepan-1-yl)-N,12-dimethyl-5-thia-3,7,10,12-tetrazatricyclo[7.3.0.02,6]dodeca-1(9),2(6),3,7,10-pentaen-8-amine
• 化学式: C₁₅H₂₀N₆S
• 分子量: 316.43
• InChiKey: HGBQLAOVJSOGBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  87.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-methyl-7-methylamino-2-(azepan-1-yl)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine 在 镍 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以46%的产率得到8-methyl-N-methyl-2-amino-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridin-5-amine
  参考文献：
  名称：

  [EN] OXAZOLYL - AND THIAZOLYL - PURINE BASED TRICYCLIC COMPOUNDS.
  [FR] COMPOSES TRICYCLIQUES A BASE D'OXAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO ET DE THIAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO, ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI

  摘要：

  公开号：

  WO2004106293A3
• 作为产物：
  描述：

  环己亚胺 、 N,8-dimethyl-2-(methylsulfonyl)-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridin-5-acetamide 在 sodium hydroxide 作用下， 以 N-甲基吡咯烷酮 、 水 为溶剂， 反应 0.67h， 以16%的产率得到4-methyl-7-methylamino-2-(azepan-1-yl)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
  参考文献：
  名称：

  [EN] OXAZOLYL - AND THIAZOLYL - PURINE BASED TRICYCLIC COMPOUNDS.
  [FR] COMPOSES TRICYCLIQUES A BASE D'OXAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO ET DE THIAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO, ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI

  摘要：

  公开号：

  WO2004106293A3

文献信息

• Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
  申请人：Pitts J. William

  公开号：US20060217412A1

  公开（公告）日：2006-09-28

  The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

  本发明提供了具有式(I)的嘧唑并咪唑基三环化合物，其中R1、R2、R3、R4、R5和R6如本文所述。本发明还提供了包含这些化合物的制药组合物，以及使用这些化合物治疗炎症和免疫性疾病的方法。
• Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
  申请人：Pitts J. William

  公开号：US20050101626A1

  公开（公告）日：2005-05-12

  The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

  本发明提供了具有式（I）的吡唑嘌呤基三环化合物、 其中 R 1 , R 2 , R 3 , R 4 , R 5 和 R 6 如本文所述。本发明进一步提供了包含此类化合物的药物组合物，以及使用此类化合物治疗炎症和免疫疾病的方法。
• Novel Tricyclic Inhibitors of IκB Kinase
  作者：James Kempson、Steven H. Spergel、Junqing Guo、Claude Quesnelle、Patrice Gill、Dominique Belanger、Alaric J. Dyckman、Tianle Li、Scott H. Watterson、Charles M. Langevine、Jagabandhu Das、Robert V. Moquin、Joseph A. Furch、Anne Marinier、Marco Dodier、Alain Martel、David Nirschl、Katy Van Kirk、James R. Burke、Mark A. Pattoli、Kathleen Gillooly、Kim W. McIntyre、Laishun Chen、Zheng Yang、Punit H. Marathe、David Wang-Iverson、John H. Dodd、Murray McKinnon、Joel C. Barrish、William J. Pitts

  DOI：10.1021/jm8015816

  日期：2009.4.9

  The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.
• US7176214B2
  申请人：——

  公开号：US7176214B2

  公开（公告）日：2007-02-13
• [EN] IMIDAZO-FUSED OXAZOLO[4,5-B]PYRIDINE AND IMIDAZO-FUSED THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME<br/>[FR] COMPOSES TRICYCLIQUES A BASE D'OXAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO ET DE THIAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO, ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004106293A2

  公开（公告）日：2004-12-09

  The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.